Breakthrough chikungunya single-dose vaccine success in Phase III trials
Phase III trials for the VLA1553 vaccine against chikungunya virus indicated promising results by inducing…
Browsing: Vaccines
What are the advantages of the Oxford—AstraZeneca COVID-19 vaccine?
While the latest set of interim vaccine results from Oxford University and AstraZeneca include an…
In Focus: studying the COVID-19 pandemic – a Special Focus Issue
Infectious Diseases Hub has partnered with Future Virology to bring you exclusive access to articles and features in the recent Special Focus Issue.
AstraZeneca COVID-19 vaccine trial resumed in the UK after safety evaluation
AstraZeneca and Oxford University (UK) have resumed the progress of their Phase III COVID-19 vaccine trial after investigating unexpected side effects in a patient enrolled in the trial in the UK.
Cytokine storm could sabotage long-term immunity against SARS-CoV-2
COVID-19 patients who develop a cytokine storm in response to infection could be unable to produce memory cells that provide long-term protection against SARS-CoV-2.
Countries with previous TB vaccine coverage show improved COVID-19 outcomes
An epidemiological study has revealed that COVID-19 outcomes are better in those countries that have undertaken a TB vaccination regime in the last 15 years.
Oxford vaccine gives strong immune response against COVID-19
The Oxford vaccine, ChAdOx1 nCoV-19, has demonstrated strong immune responses to COVID-19 in patients, as well as a good safety profile, as the results of the Phase I/II trial are published.
Novel adjuvant helps extend immunity against HIV in primates
Researchers at the Emory Vaccine Center have demonstrated that a novel adjuvant, 3M-052, can aid long-lasting immunity against HIV in rhesus monkeys. This could have implications for developing successful vaccines against HIV, influenza and COVID-19.
A closer look at the COVID-19 vaccine front-runners
A COVID-19 vaccine is widely regarded as the panacea for a fast track to normal life. There are currently over 120 vaccine candidates in development, with ten already in clinical trials. Take a look at the front-runners.
Researchers repurpose cancer immunotherapy tools for COVID-19 vaccine research
Researchers have repurposed cancer immunotherapy tools to identify regions of SARS-CoV-2 to target with a vaccine. They believe the use of this strategy could help develop a vaccine that provides long-term protection from COVID-19.